Clinical Trial Update: A Study of the Oral EGFR Inhibitor PLB1004 in Non-Small Cell Lung Cancer [Phase 1]

View source ↗

Summary

A Phase 1 clinical trial is evaluating PLB1004, an oral EGFR inhibitor, in patients with non-small cell lung cancer and is currently recruiting.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Non-small Cell Lung Cancer

Drugs mentioned

• PLB1004

Snippet

Sponsor: Avistone Biotechnology Co., Ltd. | Conditions: Non-Small Cell Lung Cancer | Phase 1 | Status: RECRUITING